Last reviewed · How we verify
Placebo of Dapagliflozin — Competitive Intelligence Brief
phase 3
Diabetes
Small molecule
Live · refreshed every 30 min
Target snapshot
Placebo of Dapagliflozin (Placebo of Dapagliflozin) — Hospital de Clinicas de Porto Alegre. This is a placebo control arm in a clinical trial and contains no active pharmaceutical ingredient.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Placebo of Dapagliflozin TARGET | Placebo of Dapagliflozin | Hospital de Clinicas de Porto Alegre | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Placebo of Dapagliflozin CI watch — RSS
- Placebo of Dapagliflozin CI watch — Atom
- Placebo of Dapagliflozin CI watch — JSON
- Placebo of Dapagliflozin alone — RSS
Cite this brief
Drug Landscape (2026). Placebo of Dapagliflozin — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-of-dapagliflozin. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab